Loading the session
Loading the session
Loading instrument
$232.02
+1.57%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +12.4% (SPY −2.6%, XLV +9.9%). 3 months: +300.8% (SPY −2.2%, XLV +13.5%). 1 year: +817.1% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MRNA, SPY and XLV · as of 3 Nov 2026
Closed at $228.44 on 3 Nov 2026: 10.2% below the 52-week high of $254.48 (21 Oct 2026) and 925.3% above the low of $22.28 (21 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
The 3 Nov 2026 close of $228.44 was 23.0% above its 50-day average ($185.79) and 158.4% above its 200-day average ($88.42). It has closed above the 200-day for 229 sessions, since 5 Dec 2025. The 50-day average crossed above the 200-day on 6 Jan 2026, 208 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
32.6M shares were sold short at the 15 Oct 2026 settlement, 8.2% of the 399.2M shares outstanding; covering them would take 1.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 3 Nov 2026 close
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
August 20, 2026
−23.55%August 19, 2026
+176.97%August 1, 2024
−21.01%